TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes
暂无分享,去创建一个
H. Thomas | Nicole Joller | G. Jhala | Tara Catterall | Prerak M. Trivedi | Tingting Ge | L. Elkerbout | David J. De George | Balasubramanian Krishnamurthy | Louis Boon | Claudia Selck | Thomas W H Kay | Chris Chiu
[1] A. Kallies,et al. Extraislet expression of islet antigen boosts T cell exhaustion to partially prevent autoimmune diabetes. , 2024, Proceedings of the National Academy of Sciences of the United States of America.
[2] S. Jonjić,et al. TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation , 2023, Nature communications.
[3] L. Piemonti,et al. Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I−/− iPSCs for β cell replacement , 2022, Cell reports.
[4] R. Germain,et al. TGF-β regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection , 2022, The Journal of experimental medicine.
[5] E. Wherry,et al. Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3 , 2022, Nature Immunology.
[6] Thomas D. Wu,et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses , 2022, Immunity.
[7] L. Boon,et al. Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor , 2022, Clinical & translational immunology.
[8] Francisco J. Sánchez-Rivera,et al. An autoimmune stem-like CD8 T cell population drives type 1 diabetes , 2021, Nature.
[9] David M. Schauder,et al. Self-Renewing Islet TCF1+ CD8 T Cells Undergo IL-27–Controlled Differentiation to Become TCF1− Terminal Effectors during the Progression of Type 1 Diabetes , 2021, The Journal of Immunology.
[10] E. Unanue,et al. Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice , 2020, Proceedings of the National Academy of Sciences.
[11] A. Dejean,et al. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. , 2020, Immunity.
[12] M. Atkinson,et al. CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation , 2020, Frontiers in Immunology.
[13] E. Choi,et al. CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy , 2020, Cancer Immunology Research.
[14] A. Oxenius,et al. TIGIT limits immune pathology during viral infections , 2020, Nature Communications.
[15] G. Freeman,et al. Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. , 2019, Immunity.
[16] S. Berger,et al. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. , 2019, Immunity.
[17] E. Wherry,et al. Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.
[18] M. Delorenzi,et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection , 2019, Nature.
[19] Yong Liu,et al. TOX is a critical regulator of tumour-specific T cell differentiation , 2019, Nature.
[20] S. Berger,et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion , 2019, Nature.
[21] F. Hodi,et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.
[22] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[23] C. D. De Block,et al. Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus , 2018, The Journal of clinical endocrinology and metabolism.
[24] Dai Fukumura,et al. Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity , 2018, The Journal of Immunology.
[25] A. Sharpe. Introduction to checkpoint inhibitors and cancer immunotherapy , 2017, Immunological reviews.
[26] A. Elkahloun,et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness , 2016, Science Immunology.
[27] James A. Eddy,et al. Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes , 2016, Science Immunology.
[28] Sandra P. Calderon-Copete,et al. T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. , 2016, Immunity.
[29] Matheus C. Bürger,et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.
[30] G. Freeman,et al. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. , 2016, Immunity.
[31] J. Hackney,et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.
[32] A. Skowera,et al. Effector-Memory T Cells Develop in Islets and Report Islet Pathology in Type 1 Diabetes , 2014, The Journal of Immunology.
[33] Z. Qiu,et al. CD226 Gly307Ser association with multiple autoimmune diseases: a meta-analysis. , 2013, Human immunology.
[34] Burton E. Barnett,et al. Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection , 2012, Science.
[35] H. Thomas,et al. Intra‐islet proliferation of cytotoxic T lymphocytes contributes to insulitis progression , 2012, European journal of immunology.
[36] D. Hafler,et al. The TIGIT/CD226 Axis Regulates Human T Cell Function , 2012, The Journal of Immunology.
[37] E. Wherry. T cell exhaustion , 2011, Nature Immunology.
[38] Vijay K. Kuchroo,et al. Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions , 2011, The Journal of Immunology.
[39] P. Muranski,et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.
[40] E. Wherry,et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.
[41] Nikhil S. Joshi,et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. , 2007, Immunity.
[42] T. Okazaki,et al. PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.
[43] T. Okazaki,et al. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] S. Khoury,et al. The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice , 2003, The Journal of experimental medicine.
[45] 廷冕 李,et al. 応用 (Application) について , 1981 .
[46] V. Kuchroo,et al. Tim-3, Lag-3, and TIGIT. , 2017, Current topics in microbiology and immunology.
[47] Y. Kawakami,et al. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. , 2016, The Journal of investigative dermatology.
[48] H. Clark,et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.